Trial reportCell reports. Medicine2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.
Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04301414 (A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Neoadjuvant Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review.Cancer medicine · 2026Pooled it
- Immunotherapy in urological cancers: new paradigms and a systematic review of clinical trials and real-world evidence.Frontiers in oncology · 2026Pooled it
- Improving Anti-CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4Cell reports. Medicine · 2026Article
- Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.Nature reviews. Urology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
Despite high rates of post-surgical recurrence in men with high-risk localized prostate cancer (PCa), there is currently no role for neoadjuvant therapy. Tumor infiltrating regulatory T cells (TI-Tregs) limit the antitumor effects of presurgical androgen deprivation therapy (ADT). We present a neoadjuvant clinical trial testing whether an afucosylated anti-CTLA-4 antibody (BMS-986218) with ADT is safe, feasible, and reduces TI-Treg frequencies. This single-center, two-arm, open-label study randomizes 24 men with high-risk localized PCa to ADT with or without BMS-986218 prior to radical prostatectomy. Treatment is well tolerated and feasible. Mechanistic studies reveal reductions in TI-Treg frequencies correlate with CD16a/FCGR3A on tumor macrophages, dendritic cell (DC) modulation, and augmented T cell priming following BMS-986218 treatment. Depth of Treg inhibition and increased DC frequencies are associated with improved clinical outcomes. Overall, this study supports the feasibility and biological activity of neoadjuvant ADT + Fc-enhanced anti-CTLA-4 in high-risk PCa. Trial is registered at clinicaltrials.gov (NCT04301414).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.